MRC-Holland MLPA. Description version 28; 4 January 2018

Size: px
Start display at page:

Download "MRC-Holland MLPA. Description version 28; 4 January 2018"

Transcription

1 SALSA MLPA probemix ME011-B3 Mismatch Repair genes Lot B and B As compared to the previous version B2 (lot B2-0614), one probe has a small change in length but no change in the sequence detected. The Mismatch Repair (MMR) system is critical for the maintenance of genomic stability. Defects in the cell s MMR system may lead to the accumulation of mutations resulting in the initiation of cancer. Several MMR genes are involved in hereditary nonpolyposis colon cancer (HNPCC). Mutations in the MLH1 and MSH2 genes have been found in about 90% of HNPCC cases. Mutations in other MMR genes are less frequently detected in HNPCC patients. In sporadic colon cancer hypermethylation is a more frequent mechanism than point mutations for transcriptional silencing of the MLH1 gene. Methylation analysis of MLH1 by MS-MLPA can improve the selection of patients for genetic testing for Lynch syndrome (Perez-Carbonell L et al. 2010, J Mol Diagn. 12: ). This ME011-B3 Mismatch Repair genes MS-MLPA probemix has been developed to detect aberrant CpG island methylation of several MMR genes and includes six probes for MLH1 (3p22.1), four probes for MSH2 (2p21), three probes for MSH6 (2p16), three probes for PMS2 (7p22), two probes for MSH3 (5q14.1), and one probe for MLH3 (14q24.3). Furthermore, this probemix contains six probes specific for the MGMT promoter region at 10q26. MGMT promoter methylation is an important molecular marker in various tumours such as glioblastomas. MGMT plays a role in removing O(6)-alkylguanine, which is the major mutagenic and carcinogenic lesion induced by alkylating mutagens. This probemix includes 22 probes containing a HhaI recognition site, which yields information about the methylation status of a target sequence. In addition, 13 reference probes are present which are not influenced by the HhaI digestion. Besides the detection of aberrant methylation, all probes present will give information on copy number changes in the analysed sample. More information about MS-MLPA can be found on page 3. This SALSA MS- probemix can be used to detect aberrant methylation of one or more sequences of the MMR genes in a DNA sample. Methylation levels can be different for different tissues. If possible, use identically treated test and reference samples (same tissue type and extraction method). This SALSA MS- probemix can also be used to detect deletions and duplications of one or more sequences of the MMR genes. Heterozygous deletions of probe recognition sequences should give a 35-50% reduced relative peak height of the amplification product of that probe. Note that a mutation or polymorphism in the sequence detected by a probe can also cause a reduction in relative peak height, even when not located exactly on the ligation site! In addition, some probe signals are more sensitive to sample purity and small changes in experimental conditions. Therefore, deletions and duplications detected by MLPA should always be confirmed by other methods. Not all deletions and duplications detected by MLPA will be pathogenic; users should always verify the latest scientific literature when interpreting their findings. Finally, note that most defects in this gene are expected to be small (point) mutations which will not be detected by this SALSA MS- test. We have no information on what percentage of defects in these genes is caused by deletions/duplications of complete exons. This SALSA MLPA probemix is not CE/FDA registered for use in diagnostic procedures. Purchase of this product includes a limited license for research purposes. The use of this SALSA MS- probemix and reagents requires a thermocycler with heated lid and sequence type electrophoresis equipment. Different fluorescent PCR primers are available. The MLPA technique has been first described in Nucleic Acid Research 30, e57 (2002). The MS-MLPA method for the detection of both copy numbers and methylation changes was described in Nucleic Acid Research 33, e128 by Nygren et al More information Website : info@mlpa.com (information & technical questions); order@mlpa.com (for orders) Mail : bv; Willem Schoutenstraat 1, 1057 DL Amsterdam, the Netherlands SALSA probemix ME011 Mismatch Repair genes Page 1 of 11

2 Related SALSA probemixes P003 MLH1/MSH2: Hereditary nonpolyposis colon cancer (HNPCC) genes included: MSH2, MLH1. P072 MSH6: HNPCC genes included: MSH6, MUTYH, EPCAM. P248 MLH1/MSH2: HNPCC confirmation genes included: MSH2, MLH1. P008 PMS2: HNPCC gene included: PMS2. References for SALSA MS- probemix ME011 Mismatch Repair genes Zauber P et al. (2017) Molecular genetic changes in benign colorectal tumors synchronous with microsatellite unstable carcinomas do not support a field defect. Int J Mol Epidemiol Genet.. 8: Takahashi K et al. (2017) Clinical characteristics of Lynch-like cases collaterally classified by Lynch syndrome identification strategy using universal screening in endometrial cancer. Gynecol Oncol. 47: Morak M et al. (2017) Loss of MSH2 and MSH6 due to heterozygous germline defects in MSH3 and MSH6. Familial cancer. 16: Kato A et al. (2016) Isolated Loss of PMS2 Immunohistochemical Expression is Frequently Caused by Heterogenous MLH1 Promoter Hypermethylation in Lynch Syndrome Screening for Endometrial Cancer Patients. Am J Surg Pathol. 40: Zauber P et al. (2015) Strong correlation between molecular changes in endometrial carcinomas and concomitant hyperplasia. Int J Gynecol Cancer. 25: Sahnane N et al. (2015) Microsatellite unstable gastrointestinal neuroendocrine carcinomas: a new clinicopathologic entity. Endocr Relat Cancer. 22: Castillejo A et al. (2015) Prevalence of MLH1 constitutional epimutations as a cause of Lynch syndrome in unselected versus selected consecutive series of patients with colorectal cancer. J Med Genet. 52: Mur P et al. (2014) Identification of a founder EPCAM deletion in Spanish Lynch syndrome families.clin Genet. 85: Crucianelli F et al. (2014) MLH1 constitutional and somatic methylation in patients with MLH1 negative tumors fulfilling the revised Bethesda criteria. Epigenetics. 9: Molenaar RJ et al. (2014) The combination of IDH1 mutations and MGMT methylation status predicts survival in glioblastoma better than either IDH1 or MGMT alone. Neuro Oncol. 16: Appelqvist F et al. (2014) Deletion of the MGMT gene in familial melanoma. Genes Chromosomes Cancer. 53: Rodríguez-Hernández I et al. (2013) Integrated analysis of mismatch repair system in malignant astrocytomas. PLoS One. 8(9):e Ozer O et al. (2013) Methylation profile analysis of DNA repair genes in hepatocellular carcinoma with MS- MLPA. Diagn Mol Pathol. 22: Jensen LH et al. (2013) Regulation of MLH1 mrna and protein expression by promoter methylation in primary colorectal cancer: a descriptive and prognostic cancer marker study. Cell Oncol. 36: Pineda M et al. (2012) MLH1 methylation screening is effective in identifying epimutation carriers. Eur J Hum Genet. 20: Gausachs M et al. (2012) MLH1 promoter hypermethylation in the analytical algorithm of Lynch syndrome: a cost-effectiveness study. Eur J Hum Genet. 20: Christians A et al. (2012) Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. PLoS One. 7:e Zauber NP et al. (2010) Microsatellite instability and DNA methylation of endometrial tumors and clinical features in young women compared with older women. Int J Gynecol Cancer. 20: Perez-Carbonell L et al. (2010) Methylation analysis of MLH1 improves the selection of patients for genetic testing in Lynch syndrome. J Mol Diagn. 12: Ligtenberg MJ et al. (2009) Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet. 41: Gylling A et al. (2009) Large genomic rearrangements and germline epimutations in Lynch syndrome. Int J Cancer. 124: Jeuken JW et al. (2007) MS-MLPA: an attractive alternative laboratory assay for robust, reliable, and semiquantitative detection of MGMT promoter hypermethylation in gliomas. Lab Invest. 87: Note: Here are the most relevant references for this probemix. PubMed and Google Scholar provide more information on the use of ME011 probemix. SALSA probemix ME011 Mismatch Repair genes Page 2 of 11

3 Please note During testing on various tumour samples, we have observed that many probes show significant signal change depending on the methylation status of the target DNA. However, as we have little access to patient samples, it is unfortunately not possible for to validate each probe on samples with known decreased mrna levels and of which the methylation status of the sequences has been confirmed by independent methods. The MS-MLPA probes target promoter regions which are unmethylated in normal blood-derived control samples, and they do not generate a signal after HhaI digestion. We have tested each probe by in vitro methylation of sample DNAs with HhaI methylase, and found that each signal indeed remains intact after HhaI digestion. Methylation-specific MLPA Please note that each MS-MLPA reaction generates two samples that need analysis by capillary electrophoresis: one undigested sample for copy number detection and one digested sample for methylation detection. A modification of the MLPA technique, MS-MLPA allows the detection of both copy number changes and unusual methylation levels of different sequences in one simple reaction. MLPA probes for methylation quantification are similar to normal MLPA probes, except that the sequence detected by the MS-MLPA probe contains the sequence recognised by the methylation-sensitive restriction enzyme HhaI. Similar to ordinary MLPA reactions, the MS-MLPA protocol starts with sample DNA denaturation and overnight hybridisation. The reaction then is split into two tubes. One tube is processed as a standard MLPA reaction. This reaction provides information on copy number changes. The other tube of the MLPA hybridisation reaction is incubated with the methylation-sensitive HhaI endonuclease while simultaneously, the hybridised probes are ligated. Hybrids of (unmethylated) probe oligonucleotides and unmethylated sample DNA are digested by the HhaI enzyme. Digested probes will not be exponentially amplified by PCR and hence will not generate a signal when analysed by capillary electrophoresis. In contrast, if the sample DNA is methylated, the hemi-methylated probe-sample DNA hybrids are prevented from being digested by HhaI and the ligated probes will generate a signal. The MS-MLPA technique should always be internally validated before use in your laboratory. Results of MS- MLPA are highly dependent on the HhaI enzyme used. HhaI enzymes that are resistant to heat inactivation are NOT compatible with the MS-MLPA technique and will give aberrant results. These include, but may not be limited to, Thermo Fisher Scientific enzymes HhaI, ANZA 59 HhaI, and FastDigest HhaI. We recommend using Promega s HhaI enzyme (R6441) as this is the only restriction enzyme that has been validated for use with MS-MLPA by. More information about MS-MLPA can be found in the MS-MLPA protocol. Please note that this product can not be used with an alternative protocol in which the genomic DNA is first digested with HhaI, followed by MLPA reactions on both digested and undigested genomic DNA. Data analysis The ME011-B3 Mismatch Repair genes probemix contains 38 MLPA probes with amplification products between 130 and 418 nt. In addition, it contains 9 control fragments generating an amplification product smaller than 120 nt: four DNA Quantity fragments (Q-fragments) at nt, three DNA Denaturation control fragments (D-fragments) at nt, one X-fragment at 100 nt and one Y-fragment at 105 nt. More information on how to interpret observations on these control fragments can be found in the MLPA protocol. The analysis of MS-MLPA probemixes consists of two parts: 1) determining copy numbers by comparing different undigested samples, and 2) determining methylation patterns by comparing each undigested sample to its digested counterpart (MS-MLPA probemixes only). The second part is unique for MS-MLPA probemixes and serves to semi-quantify the percentage of methylation within a given sample. 1) Copy number analysis - Selection of reference probes SALSA probemix ME011 Mismatch Repair genes Page 3 of 11

4 First select suitable reference probes for copy number detection. These are probes detecting relatively quiet regions in the particular type of tumour studied. The reference probes selected will therefore depend on the application. Probes that are suitable to use for reference in many types of tumour are indicated in Table 1. - Intra-sample data normalisation For analysis of MLPA results, not the absolute fluorescence values but intra-normalised data are used (relative peak heights). The data generated in the undigested sample should first be normalised intra-sample by dividing the signal of each probe by the signal of every reference probe in that sample, thus creating as many ratios per probe as there are reference probes. Subsequently, the median of all these produced ratios per probe should be taken; this is the probe s Normalisation Constant. This Normalisation Constant can then be used for sample to reference sample comparison. - Inter-sample normalisation (comparison with reference samples) The final probe ratio, or ploidy status, of each probe in each sample is calculated by dividing a) the Normalisation Constant of each probe obtained on the undigested test sample by b) the average Normalisation Constant of that probe obtained on the undigested reference samples. 2) Methylation analysis - Selection of reference probes Use the reference probes for methylation as marked in Table 1. All reference probes used for methylation analysis do not contain a HhaI site. - Intra-sample data normalisation For analysis of MLPA results, not the absolute fluorescence values but intra-normalised data are used (relative peak heights). The data generated in the digested sample should first be normalised intra-sample by dividing the signal of each probe by the signal of every reference probe in that sample, thus creating as many ratios per probe as there are reference probes. Subsequently, the median of all these produced ratios per probe should be taken; this is the probe s Normalisation Constant. This Normalisation Constant can then be used for sample to reference sample comparison. - Methylation analysis (comparison with reference samples) The methylation status of each MS-MLPA probe* in each sample is calculated by dividing a) the Normalisation Constant of each probe obtained on the digested test sample by b) the Normalisation Constant of each MS- MLPA probe obtained on the corresponding undigested sample. Multiplying this value by 100 gives an estimation of the percentage of methylation. Aberrant methylation can then be identified by comparing the methylation status of one or more MS-MLPA probes in the sample in question to that obtained on reference samples. *Note: An MS-MLPA probe usually targets a single specific HhaI site in a CpG island; if methylation is absent for a particular CpG-site, this does not necessarily mean that the whole CpG island is unmethylated! Data normalisation should be performed within one experiment. Only samples purified by the same method should be compared. Confirmation of most exons deletions and amplifications can be done by e.g. Southern blotting, long range PCR, qpcr, FISH. Warning: MLPA analysis on tumour samples provides information on the average situation in the cells from which the DNA sample was purified. Gains or losses of genomic regions or genes may not be detected if the percentage of tumour cells is low. Furthermore, there is always a possibility that one or more reference probes do show a copy number alteration in a sample. Normal copy number variation in healthy individuals is described in the database of genomic variants: When in doubt, users should always verify the latest updates of the database and scientific literature when interpreting their findings. Note that Coffalyser.Net, the MLPA analysis tool developed at, can be downloaded free of charge from our website This probemix was developed at. Info/remarks/suggestions for improvement: info@mlpa.com. SALSA probemix ME011 Mismatch Repair genes Page 4 of 11

5 Table 1. SALSA MS-MLPA ME011-B3 Mismatch Repair genes probemix Length (nt) SALSA MLPA probe HhaI site % expected signal reduction Chromosomal position MV location (HG18) Q-fragments: DNA quantity; only visible with less than 100 ng sample DNA D-fragments: Low signal of 88 or 96 nt fragment indicates incomplete denaturation 100 X-fragment: Specific for the X chromosome 105 Y-fragment: Specific for the Y chromosome 130 Reference probe L q Reference probe L q PMS2 probe L p MLH1 probe L p PMS2 probe L p MSH6 probe L p MLH1 probe L p MGMT probe L q Reference probe L p MSH2 probe L p Reference probe L p MLH1 probe L p MGMT probe L q MSH6 probe L p MGMT probe L q MSH3 probe L q Reference probe L q MLH1 probe L p MSH2 probe L p Reference probe L q MLH1 probe L p MSH2 probe L p MSH3 probe L q MLH1 probe L p MSH6 probe L p Reference probe L p Reference probe L q Reference probe L p PMS2 probe L p ๑ MGMT probe L q MLH3 probe L q Reference probe L p Reference probe L q Reference probe L q «MGMT probe L q MSH2 probe L p ๑ MGMT probe L q Reference probe L p Changed in version B3 (from lot B onwards). Small change in length, no change in sequence detected. Target sequence of this probe contains SNP rs (C/T) in the GCGC site, 6 nt right from the ligation site. When the T-allele of this validated SNP (with an allele frequency of 0.068%) is present, HhaI digestion will not occur, resulting in a false methylated site. «This probe is located within, or close to, a very strong CpG island. A low signal of this probe can be due to incomplete sample DNA denaturation, e.g. due to the presence of salt in the sample DNA. + The genomic region targeted by this reference probe is reported to be variable in healthy individuals according to database of genomic variants. More variable. This probe has a high standard deviation. This probe may be sensitive to certain experimental variations. Aberrant results should be treated with caution. ๑ The significance of methylation of CpG site targeted by this probe is not clear. Note: The identity of the genes detected by the reference probes is available in Table 2b. Please notify us of any mistakes: info@mlpa.com. SALSA probemix ME011 Mismatch Repair genes Page 5 of 11

6 Table 2. ME011 probes arranged according to chromosomal location Table 2a. Target probes arranged according to chromosomal location. Length (nt) SALSA MLPA probe Gene/ Exon Ligation site Partial sequence, for copy number probes (24 nt adjacent to ligation site)/ Complete sequence, for MS-MLPA probes (HhaI site is highlighted in grey) Distance to next probe MSH2, at 2p21 The indicated ligation sites are in the NM_ sequence (NG_ ), with the MSH2 start codon at nt in exon L07711 Upstream 144 nt before exon 1; 269 nt before ATG, reverse GAAACCCGCAGACGCGCATCCT- TAGTAGAGCTCCTTTCTGTGTTTACTCAGCTGCAAGGC TTG CGCAGTAGCTAAAGTCACCAGCGTGCGCGGGA- AGCTGGGCCGCGTCTGCTTATGATTGGTTGCCGC L13115 Upstream 67 nt before exon 1; 192 nt before ATG 0.3 kb L00599 Exon ; CCTTTTCGACCGGGGCGACTTCT- 124 nt after ATG ATACGGCGCACGGCGAGGACGCGCTGCTG 26.5 kb L12398 Exon AGACAAGCAGCA-AACTTACAAGAT kb MSH6, at 2p16.3 The indicated ligation sites are in the NM_ sequence (NG_ ), with the MSH6 start codon at nt in exon 1. Another MSH6 exon 1 MS-MLPA probe is present in the ME-002 probemix L05732 Upstream L05733 Exon L05731 Exon nt before exon 1; 317 nt before ATG 26-27; 126 nt before ATG ; 49 nt before ATG, reverse CCAGCCCCGCGGCGTGAGGGA- AGGGGAGCTCAGCAGTTCCCCGCGCGGGGCC CGAGGCGCCTGTTGATTGGCCACT- GGGGCCCGGGTTCCTCCGGCGGAGCGCGCCT CGTTCTGTCGGACGGAGCTCCTAAAA- GCACCGCATCTACCGCGCGGCTCCTGCTGGCGGGAAA TCTG MLH1, at 3p22.2 The most important methylation region for MLH1 expression, the Deng C-region, is from -248 nt to -178 nt before the transcription start site. The transcription start site that Deng G et al. (1999) used for reference lies 21 nt before the ATG start codon. The second most important region, the Deng D-region, is from -9 nt to +15 nt (Capel E et al. 2007, Oncogene. 26: ; Deng G et al. 1999, Cancer Research. 59: ). For this reason, methylation of the 196 nt and 166 nt probes will be the most important determinant for mrna expression. It is not possible for us to design extra MLPA probes in these regions as there are no other HhaI sites. Methylation of the Deng A and B regions is not specifically correlated with loss of MLH1 expression. The indicated ligation sites are in the NM_ sequence (NG_ ), with the MLH1 start codon at nt in exon L07710 Upstream L01265 Upstream L01747 Upstream L07712 Upstream L15580 Exon L01745 Intron nt before exon 1; 658 nt before ATG (Deng, A-region) 319 nt before exon 1; 517 nt before ATG (Deng, B-region) 184 nt before exon 1; 382 nt before ATG, reverse (Deng, B-region) 47 nt before exon 1; 245 nt before ATG (Deng, C-region) ; 12 nt before ATG (Deng, D-region) 93 nt after exon 1; 206 nt after ATG TCCGCCACATACCGCTCGTAGTAT- TCGTGCTCAGCCTCGTAGTGGCGCCTGACGTCGCGTT GGCCGGAAAACT-AGAGCCTCGTCG CTGCTGAGGTGATCTGGCGCAGA- GCGGAGGAGGTGCTTGGCGCTTCTCAGGCTCCTCCTC T AAGAGCGGACAGCGATCTCTAACGCGCAA- GCGCATATCCTTCTAGGTAGCGGGCAGTAGCCGCTTCA GG TGAGCATCTAGACGTTTCCTTGGCTCT- TCTGGCGCCAAAATGTCGTTCGTGGCAGGGGTTATTC CGGACACGCCTCTTTGCCCGGGCAGA- GGCATGTACAGCGCATGCCCACAACGGCGGAGGCC MSH3, at 5q14.1 The indicated ligation sites are in the NM_ sequence (NG_ ), with the MSH3 start codon at nt in exon nt before exon 1; TTTCTGCTGCGCGGGAGGCCCAGT L14208 Upstream 0.6 kb 485 nt before ATG, reverse TGCTGATTTCTGCCCGGATTCTGCTGCCCGGTGAGGTCTT L00795 Exon TTTTGAGCCGAT-TCTTCCAGTCTA SALSA probemix ME011 Mismatch Repair genes Page 6 of 11

7 Length (nt) SALSA MLPA probe Gene/ Exon Ligation site Partial sequence, for copy number probes (24 nt adjacent to ligation site)/ Complete sequence, for MS-MLPA probes (HhaI site is highlighted in grey) Distance to next probe PMS2, at 7p22.1 The indicated ligation sites are in the NM_ sequence (NG_ ), with the PMS2 start codon at nt in exon L13112 Intron 1 20 nt after exon 1; 40 nt after ATG, reverse L16571 Exon ; 62 nt before ATG L16147 Upstream 219 nt before exon 1; 306 nt before ATG GCTCGAGGTGAGCGGGGCTCGCAGTCT- TCCGGTGTCCCCTCTCGCGCGCCCTCTTTGAGAC GCCAATGGGAGTTCAGGAGGCGGA- GCGCCTGTGGGAGCCCTGGAGGGAACTTTCCCAGT GGCAGAACCAAAGCAAAAGGGGGTAGCGCGTGCCAAAG -GCCAACGCTCAGAAACCGTCAGAGGTCACGACGGAGAC MGMT, at 10q26.3 Two methylation hot spots near the transcription start site denote silencing of the MGMT gene (Qian XC and Brent TP. 1997, Cancer Res. 57:3672-7). Between these methylation hot spots is a region which is much less frequently methylated (see Figure 3 in the article of Qian and Brent). This ME011-B3 probemix includes six MS-MLPA probes for the MGMT region surrounding the transcription and translation start sites. Based on the article of Qian and Brent, as well as data obtained with this probemix by Judith Jeuken (Nijmegen), we currently recommend disregarding the results obtained with the 346 nt probe (located between the methylation hot spots and showing methylation in only rare cases) and the 409 nt probe (which shows frequent methylation, but at times in cases where the other five probes do not show any methylation). More information on the MGMT probes can be found on page 8. More MGMT probes can be found in the SALSA MLPA probemix ME012-A MGMT-IDH1-IDH2. The indicated ligation sites are in the NM_ sequence, with the MGMT start codon at nt in exon «14136-L12791 Upstream L14276 Upstream 346 ๑ L15582 Upstream L14205 Intron L15736 Intron ๑ L16573 Intron nt before exon 1; 432 nt before ATG, reverse 314 nt before exon 1; 345 nt before ATG 61 nt before exon 1; 93 nt before ATG, reverse 73 nt after exon 1; 151 nt after ATG 154 nt after exon 1; 232 nt after ATG, reverse 385 nt after exon 1; 463 nt after ATG, reverse CGTGCAAGCGACCTGCCACGT- GCCCGAGTGGTCCTGAAAGCGCGCGGGGGTCGTAGGA CGGCGCCCGCTTAGTGAGA CGGGCCATTTGGCAAACTAAGGCACAGAGCCTCA- GGCGGAAGCTGGGAAGGCGCCGCCCGGCTTGTAC GCGGAGCCGAGGACCTGAGAAAAGCAA- GAGAGCGCGCGGGGGCGGGGCCGGG TCGGGACGGTGGCAGCCTCGAGTGGT- CCTGCAGGCGCCCTCACTTCGCCGTCGGGTGT GAAAGGCTGGGCAACACCTGGGAGGCACTT- GGGGCGCACCTGGAGCTCGCCCGGGATGGGT GGACTCTGCCTAAGTATGCTAAAGGGTTGCTGCAA- GCCAAGGCCCGCGCAGGGGCTTCTGGAAGCTTCCT MLH3, at 14q24.3 The indicated ligation sites are in the NM_ sequence (NG_ ), with the MLH3 start codon at nt in exon L07722 Exon ; 1792 nt before ATG CGTGGGCACGCACGAGCCTCA- AGATCCAAGGTGCGCGCGTCGGCGTCCGAGG The HhaI sites are marked in grey. Ligation sites are marked with -. Target sequence of this probe contains SNP rs (C/T) in the GCGC site, 6 nt right from the ligation site. When the T-allele of this validated SNP (with an allele frequency of 0.068%) is present, HhaI digestion will not occur, resulting in a false methylated site. «This probe is located within, or close to, a very strong CpG island. A low signal of this probe can be due to incomplete sample DNA denaturation, e.g. due to the presence of salt in the sample DNA. + The genomic region targeted by this reference probe is reported to be variable in healthy individuals according to database of genomic variants. More variable. This probe has a high standard deviation. This probe may be sensitive to certain experimental variations. Aberrant results should be treated with caution. This probe is also present in the SALSA MLPA probemix ME012-A MGMT-IDH1-IDH2. ๑ The significance of methylation of CpG site targeted by this probe is not clear. Notes Exon numbering used here may differ from literature! Please notify us of any mistakes: info@mlpa.com. Please note that several probes have multiple HhaI restriction sites. All of these sites need to be methylated in order to not be digested! kb - - SALSA probemix ME011 Mismatch Repair genes Page 7 of 11

8 Table 2b. Reference probes arranged according to chromosomal location. Length (nt) SALSA MLPA probe Gene Location Partial sequence (24 nt adjacent to ligation site) L04144 ABCB4 7q21 ACCAGTGTCCTT-TCTGAAGGTCCT L19330 TSC1 9q34 CAGCGTGACACT-ATGGTAACCAAG L00781 CELF2 (LINC00710) 10p14 GACATTCACTGT-GGAAATTTGGTG L04802 KCNQ1 11p15 TGGGCCTCATCT-TCTCCTCGTACT L00020 CTTN 11q13 AGGCAGAGCTGA-GCTACAGAGGCC L13113 TNFRSF1A 12p13 CCCTGAGCCCAA-ATGGGGGAGTGA L13114 PAH 12q23 GGTTCCCAAGAA-CCATTCAAGAGC L01903 FBN1 15q21 CAGTGTCCCAGT-GGAATGACTTTG L12763 TSC2 16p13 TGGCTCTGGCTT-TCACCATCCTCT L09804 SEPT9 17q25 AGCTGGATCAGA-TCTGAATCCAGA L15938 CACNA1A 19p13 CTCAGGCCTTCT-ACTGGACTGTAC L12774 PROKR2 20p12 ATTGCACTGGCA-GGCATCATGCTG L04594 KCNJ6 21q22 CTCGAAGCTCCT-ACATCACCAGTG MGMT probes in ME011 GGTCTCTGCTGGTCTGGGGGTCCCTGACTAGGGGAGCGGCACCAGGAGGGGAGAGACTCG CGCTCCGGGCTCAGCGTAGCCGCCCCGAGCAGGACCGGGATTCTCACTAAGCGGgcgcCG 1 TCCTACGACCCCCgcgcGCTTTCAGGACCACTCGGGCACGTGGCAGGTCGCTTGCACGCC 2 CGCGGACTATCCCTGTGACAGGAAAAGGTACGGGCCATTTGGCAAACTAAGGCACAGAGC CTCAGGCGGAAGCTGGGAAGgcgcCGCCCGGCTTGTACCGGCCGAAGGGCCATCCGGGTC 3 AGgcgcACAGGGCAGCGgcgcTGCCGGAGGACCAGGGCCGGCGTGCCGGCGTCCAGCGAG 4+5 GATgcgcAGACTGCCTCAGGCCCGgcgcCGCCGCACAGGGCATgcgcCGACCCGGTCGGG CGGGAACACCCCGCCCCTCCCGGGCTCCGCCCCAGCTCCGCCCCCgcgcGCCCCGGCCCC 9 GCCCCCgcgcGCTCTCTTGCTTTTCTCAGGTCCTCGGCTCCGCCCCGCTCTAGACCCCGC 10 CCCACGCCGCCATCCCCGTGCCCCTCGGCCCCGCCCCCgcgcCCCGGATATGCTGGGACA 11 GCCCgcgcCCCTAGAACGCTTTGCGTCCCGACGCCCGCAGGTCCTCGCGGTgcgCACCGT TTGCGACTTGGTGAGTGTCTGGGTCGCCTCGCTCCCGGAAGAGTGCGGAGCTCTCCCTCG GGACGGTGGCAGCCTCGAGTGGTCCTGCAGgcgcCCTCACTTCGCCGTCGGGTGTGGGGC 14 CGCCCTGACCCCCACCCATCCCGGGCGAGCTCCAGGTgcgcCCCAAGTGCCTCCCAGGTG 15 TTGCCCAGCCTTTCCCCGGGCCTGGGGTTCCTGGACTAGGCTGCGCTGCAGTGACTGTGG 16 ACTGGCGTGTGGCGGGGGTCGTGGCAGCCCCTGCCTTACCTCTAGGTGCCAGCCCCAGGC CCGGGCCCCGGGTTCTTCCTACCCTTCCATGCTGCCAGCTTTCCCTCCGCCAGCTGCTCC AGGAAGCTTCCAGAAGCCCCTgcgcGGGCCTTGGCTTGCAGCAACCCTTTAGCATACTTA 17 ATG = translation start codon CTC = mrna start (NM_ ) gcgc: HhaI sites 1 to 17 Bold/Italic: SNPs according to dbsnp141 Grey text: repeat region according to UCSC Genome Browser website Underlined is the MGMT coding sequence of exon 1. In Italic/Underlined the primers are marked (as used by Danam RP et al. 2005, Mol Cancer Ther. 4:61-69) to amplify the hot spot 1 region located from -250 nt to -101 nt with respect to the transcription start. Hot spot 2 region is located between +97 nt and +196 nt from the transcription start. MGMT probes in the ME011-B probemix (lots 1009, 0710, 0913, 0614, 0715, 1017): Probe L12791 (391 nt) is sensitive to methylation of HhaI sites 1+2 (reverse) Probe L14276 (202 nt) is sensitive to methylation of HhaI site 3 Probe L15582 (346 nt) is sensitive to methylation of HhaI site 10 (reverse) Probe L14205 (214 nt) is sensitive to methylation of HhaI site 14 Probe L15736 (172 nt) is sensitive to methylation of HhaI site 15 (reverse) Probe L16573 (409 nt) is sensitive to methylation of HhaI site 17 (reverse) SALSA probemix ME011 Mismatch Repair genes Page 8 of 11

9 SALSA MLPA probemix ME011-B3 Mismatch Repair genes sample pictures Figure 1. Capillary electrophoresis pattern of a sample of approximately 50 ng undigested human male control DNA analysed with SALSA MLPA probemix ME011-B3 Mismatch Repair genes (lot B3-1017) for the quantification of copy numbers. Figure 2. Capillary electrophoresis pattern of a sample of approximately 50 ng digested human male control DNA analysed with SALSA MLPA probemix ME011-B3 Mismatch Repair genes (lot B3-1017) to determine the methylation status. SALSA probemix ME011 Mismatch Repair genes Page 9 of 11

10 Implemented Changes compared to the previous product description version(s). Version 28 4 January 2018 (16) - New references added for ME011 on page 2. - Lengths of several probes have been modified to reflect the true amplification length in Table 1 and Table 2. - Added MV location (HG18) column in Table 1 and removed from Table 2a and 2b. - Removed two columns from Table 1 indicating whether the probes are used as references for copy number and/or methylation analysis. - Added footnotes about variable probes and non-significant MGMT MS-MLPA probes in Table 1 and Table 2a. - Added a footnote about the MGMT probes in ME012 probemix in Table 2a. - Added Distance to the next probe column in Table 2a. - Modified NM-sequence and ligation site information for MGMT probes in Table 2a. - Updated the NM-sequence version for PMS2 probes in Table 2a. - Split Table 2 into Table 2a (target probes) and Table 2b (reference probes). - Added a note about multiple GCGC sites in one MS-MLPA probe on page 7. - Modified formatting of MGMT probe sequences on page 8 for easier visualisation on black and white print. - Removed paragraph on page 8 about MGMT probed in the previous ME011-A1 version. Version September 2017 (16) - Three probes (01685-L01265, L12398, L00795) adjusted in Table 1 as not being reference probes for methylation in the Reference Probe for methylation column. Version February 2017 (16) - Probe length adjusted for reference probe L04594 in Table 1 and 2. - Probe length adjusted for MGMT probe L16573 in Table 1. - Minor textual and layout changes. - List of related SALSA MLPA probemixes updated. Version December 2016 (16) - Warning regarding HhaI enzymes that are resistant to heat inactivation added under Methylation-specific MLPA section. Version October 2015 (15) - Product description adapted to a new product version (version number changed, lot number added, small changes in Table 1 and Table 2, new pictures included). - Footnotes added for Table 1 and 2. - Expected signal reduction percentages added to Table 1. - References modified on page 2. Version May 2015 (14) - Product description adapted to a new product version (version number changed, lot number added, small changes in Table 1 and Table 2, new pictures included). Version 22 (13) - New references added on page 2. Version 21 (13) - Product description adapted to a new product version (product version number and lot number changed, small changes in Table 1 and Table 2, new pictures included). - New references added on page 1. Version 20 (12) - Product description adapted to a new product version (version number and lot number changed, small changes in Table 1 and Table 2, new picture included). - New references added on page 1. Version 19 (8) - Electropherogram pictures using the new MLPA buffer (introduced in December 2012) added. Version 18 (8) - The ligation sites for the MSH2 probes are now indicated in Table 2 according to the new version of the reference sequence NM_ Version 17 (8) SALSA probemix ME011 Mismatch Repair genes Page 10 of 11

11 - Various minor textual changes. - The gene name has changed for the following probe: 364 nt (probe L00781). - Ligation sites have been updated according to new version of the NM_reference sequence Version 16 (6) - Note added about SNP present in MLH1 probe L15580 (166 nt) added to Table 1 and Table 2. Version 15 (6) - Product description adapted to a new lot (lot number added, changes in Table 1 and 2, new picture). - Various minor textual changes on page 1. Version 14 (6) - Two extra references added on page 2. Version 13 (6) - Various textual changes in table 2. - Information added about the MGMT probes on page 7. Version 12 (6) - Product description adapted to a new lot (lot number added, changes in Table 1/2, new picture). - Various minor textual changes on page 1, various minor layout changes, tables have been numbered. - Data analysis section has been modified. For copy number analysis and methylation analysis different reference probes should be used (see Table 1). SALSA probemix ME011 Mismatch Repair genes Page 11 of 11

SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407

SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 SALSA MS-MLPA KIT ME011-A1 Mismatch Repair genes (MMR) Lot 0609, 0408, 0807, 0407 The Mismatch Repair (MMR) system is critical for the maintenance of genomic stability. MMR increases the fidelity of DNA

More information

MRC-Holland MLPA. Description version 29;

MRC-Holland MLPA. Description version 29; SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,

More information

MRC-Holland MLPA. Description version 08; 30 March 2015

MRC-Holland MLPA. Description version 08; 30 March 2015 SALSA MLPA probemix P351-C1 / P352-D1 PKD1-PKD2 P351-C1 lot C1-0914: as compared to the previous version B2 lot B2-0511 one target probe has been removed and three reference probes have been replaced.

More information

SALSA MLPA probemix P315-B1 EGFR

SALSA MLPA probemix P315-B1 EGFR SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional

More information

MRC-Holland MLPA. Description version 18; 09 September 2015

MRC-Holland MLPA. Description version 18; 09 September 2015 SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the

More information

MRC-Holland MLPA. Description version 06; 23 December 2016

MRC-Holland MLPA. Description version 06; 23 December 2016 SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated

More information

MRC-Holland MLPA. Description version 14; 28 September 2016

MRC-Holland MLPA. Description version 14; 28 September 2016 SALSA MLPA probemix P279-B3 CACNA1A Lot B3-0816. As compared to version B2 (lot B2-1012), one reference probe has been replaced and the length of several probes has been adjusted. Voltage-dependent calcium

More information

MRC-Holland MLPA. Description version 29; 31 July 2015

MRC-Holland MLPA. Description version 29; 31 July 2015 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082

More information

MRC-Holland MLPA. Description version 30; 06 June 2017

MRC-Holland MLPA. Description version 30; 06 June 2017 SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are

More information

MRC-Holland MLPA. Description version 12; 13 January 2017

MRC-Holland MLPA. Description version 12; 13 January 2017 SALSA MLPA probemix P219-B3 PAX6 Lot B3-0915: Compared to version B2 (lot B2-1111) two reference probes have been replaced and one additional reference probe has been added. In addition, one flanking probe

More information

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted.

SALSA MLPA probemix P169-C2 HIRSCHSPRUNG-1 Lot C As compared to version C1 (lot C1-0612), the length of one probe has been adjusted. mix P169-C2 HIRSCHSPRUNG-1 Lot C2-0915. As compared to version C1 (lot C1-0612), the length of one has been adjusted. Hirschsprung disease (HSCR), or aganglionic megacolon, is a congenital disorder characterised

More information

MRC-Holland MLPA. Description version 05; 03 April 2019

MRC-Holland MLPA. Description version 05; 03 April 2019 SALSA MLPA probemix ME012-A1 MGMT-IDH1-IDH2 Lot A1-1215. Glioblastoma, the most common malignant primary brain tumour, is characterised by aggressive behaviour and a poor survival. Hypermethylation in

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent diabetes

More information

P323-B1 CDK4-HMGA2-MDM2

P323-B1 CDK4-HMGA2-MDM2 SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0714, B1-0711. As compared to previous test version (lot A1-0508), this probemix has been completely redesigned. Probes for HMGA2 and several other genes

More information

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced.

SALSA MLPA probemix P241-D2 MODY mix 1 Lot D2-0716, D As compared to version D1 (lot D1-0911), one reference probe has been replaced. mix P241-D2 MODY mix 1 Lot D2-0716, D2-0413. As compared to version D1 (lot D1-0911), one reference has been replaced. Maturity-Onset Diabetes of the Young (MODY) is a distinct form of non insulin-dependent

More information

MRC-Holland MLPA. Description version 08; 18 November 2016

MRC-Holland MLPA. Description version 08; 18 November 2016 SALSA MLPA probemix P122-D1 NF1 AREA Lot D1-1016. As compared to lot C2-0312, four probes in the NF1 area and one reference probe have been removed, four reference probes have been replaced and several

More information

MRC-Holland MLPA. Description version 07; 26 November 2015

MRC-Holland MLPA. Description version 07; 26 November 2015 SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced

More information

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.

New: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix. SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:

More information

Product Description SALSA MS-MLPA Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol.

Product Description SALSA MS-MLPA Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol. Product Description SALSA MS- Probemix ME011-C1 Mismatch Repair Genes To be used with the MS-MLPA General Protocol. Version C1. As compared to the previous version (lot B3-1017), this probemix has been

More information

MRC-Holland MLPA. Description version 08; 07 May 2015

MRC-Holland MLPA. Description version 08; 07 May 2015 mix P185-C1 Intersex Lot C1-0611: As compared to the previous version B2 (lot B2-0311), s for CYP21A2 have been removed and s for the CXorf21 gene as well as additional s for NR0B1, NR5A1 and the Y chromosome

More information

MRC-Holland MLPA. Description version 06; 07 August 2015

MRC-Holland MLPA. Description version 06; 07 August 2015 SALSA MLPA probemix P323-B1 CDK4-HMGA2-MDM2 Lot B1-0711. As compared to version A1 (test version sent to test labs), this product has been completely redesigned. Probes for HMGA2 and several other genes

More information

MRC-Holland MLPA. Description version 13;

MRC-Holland MLPA. Description version 13; SALSA MLPA probemix P027-C1 Uveal Melanoma Lot C1-0211: A large number of probes have been replaced by other probes in the same chromosomal regions as compared to previous lots, and several reference probes

More information

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment).

Most severely affected will be the probe for exon 15. Please keep an eye on the D-fragments (especially the 96 nt fragment). SALSA MLPA probemix P343-C3 Autism-1 Lot C3-1016. As compared to version C2 (lot C2-0312) five reference probes have been replaced, one reference probe added and several lengths have been adjusted. Warning:

More information

SALSA MLPA KIT P050-B2 CAH

SALSA MLPA KIT P050-B2 CAH SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to

More information

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted.

SALSA MLPA probemix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four probes have been adjusted. mix P185-C2 Intersex Lot C2-1015: As compared to the previous version C1 (lot C1-0611), the lengths of four s have been adjusted. The sex-determining region on chromosome Y (SRY) is the most important

More information

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B

SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B SALSA MLPA probemix P372-B1 Microdeletion Syndromes 6 Lot B1-1016, B1-0613. The purpose of the P372 probemix is to further investigate results found with the P245 Microdeletion Syndromes-1A probemix. The

More information

MRC-Holland MLPA. Description version 19;

MRC-Holland MLPA. Description version 19; SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL

More information

PRADER WILLI/ANGELMAN

PRADER WILLI/ANGELMAN SALSA MS-MLPA probemix ME028-B2 PRADER WILLI/ANGELMAN Lot B2-0811: As compared to version B1 (lot B1-0609, B1-1108), the 88 and 96 nt control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME

More information

SALSA MLPA KIT P060-B2 SMA

SALSA MLPA KIT P060-B2 SMA SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the

More information

MRC-Holland MLPA. Description version 23; 15 February 2018

MRC-Holland MLPA. Description version 23; 15 February 2018 SALSA MLPA probemix P225-D2 PTEN Lot D2-0315. As compared to the previous version (lot D1-0613), one probe has a small change in length but no change in the sequence detected. PTEN is a tumour suppressor

More information

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.

MRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53. SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,

More information

MRC-Holland MLPA. Description version 52; 22 July 2015

MRC-Holland MLPA. Description version 52; 22 July 2015 SALSA MS-MLPA probemix ME028-B2 Prader-Willi/Angelman Lot B2-0413, lot B2-0811. As compared to version B1 (lot B1-0609), the control fragments have been replaced (QDX2). PRADER-WILLI SYNDROME (PWS) and

More information

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509

SALSA MLPA probemix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 mix P371-A1 Microdeletion Syndromes 5 Lot A1-0509 The purpose of the P371 mix is to further investigate results found with the P245 Microdeletion mix. The P245 mix provides a possibility to screen samples

More information

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A

SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A SALSA MLPA probemix P360-A1 Y-Chromosome Microdeletions Lot A1-1011. This SALSA MLPA probemix is for basic research and intended for experienced MLPA users only! This probemix enables you to quantify genes

More information

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B

SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B and B SALSA MLPA Probemix P014-B1 Chromosome 8 Lot B1-0916 and B1-0713. Copy number changes of the human chromosome 8 are common in many types of tumours. In most cases, losses of 8p sequences and gains of 8q

More information

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length.

SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. SALSA MLPA probemix P175-A3 Tumour Gain Lot A3-0714: As compared to the previous version A2 (lot A2-0411), nine probes have a small change in length. This SALSA probemix is for basic research only! This

More information

SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109

SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109 SALSA MLPA KIT P078-B1 Breast Tumour Lot 0210, 0109 This P078-B1 Breast Tumour probemix contains probes for several genes (including ERBB2, BIRC5, MYC, TOP2A, ESR1, MTDH, CCND1, CCNE1, EGFR and C11orf30)

More information

MRC-Holland MLPA. Description version 23; 26 January 2017

MRC-Holland MLPA. Description version 23; 26 January 2017 SALSA MLPA probemix ME024-B2 9p21 CDKN2A/2B region Lot B2-0615. As compared to the previous version B1 (lot B1-0411), one flanking probe is redesigned, two reference probes are replaced, and several probes

More information

SALSA MLPA probemix P383-A1 T-ALL Lot A

SALSA MLPA probemix P383-A1 T-ALL Lot A SALSA MLPA probemix P383-A1 T-ALL Lot A1-0213. T-lineage acute lymphoblastic leukaemia (T-ALL) is a clonal malignant disorder of immature T-cells, which accounts for about 15% of paediatric and 25% of

More information

Product Description SALSA MS-MLPA Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol.

Product Description SALSA MS-MLPA Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol. Product Description SALSA MS- Probemix ME028-C1 Prader-Willi/Angelman To be used with the MS-MLPA General Protocol. Version C1. For complete product history see page 9. Catalogue numbers: ME028-025R: SALSA

More information

Product Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Product Description SALSA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19

More information

Product Description SALSA MLPA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol. Product Description SALSA Probemix P027-C2 Uveal melanoma To be used with the MLPA General Protocol. Version C2. As compared to version C1, three reference probes have been replaced and the lengths of

More information

Product Description SALSA MLPA Probemix P055-D1 PAH To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P055-D1 PAH To be used with the MLPA General Protocol. Product Description SALSA Probemix P055-D1 PAH To be used with the MLPA General Protocol. Version D1. For complete product history see page 7. Catalogue numbers: P055-025R: SALSA MLPA probemix P055 PAH,

More information

Product Description SALSA MLPA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol. Product Description SALSA Probemix P138-C1 SLC2A1-STXBP1 To be used with the MLPA General Protocol. Version C1. For complete product history see page 7. Catalogue numbers: P138-025R: SALSA MLPA probemix

More information

MRC-Holland MLPA. Description version 10; 06 April 2018

MRC-Holland MLPA. Description version 10; 06 April 2018 Description version ; 6 April 8 mix P36-B Y-Chromosome Microdeletions Lot B-5. As compared to version A (Lot A-), all probes f DPY9L, one probe f RBMYCP and one probe f KDM5D have been removed, and one

More information

Lynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017

Lynch Syndrome Screening for Endometrial Cancer: Basic Concepts 1/16/2017 1 Hi, my name is Sarah Kerr. I m a pathologist at Mayo Clinic, where I participate in our high volume Lynch syndrome tumor testing practice. Today I hope to cover some of the basics needed to understand

More information

Product Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Product Description SALSA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19

More information

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction

Abstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant

More information

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014

Policy Specific Section: Medical Necessity and Investigational / Experimental. October 14, 1998 March 28, 2014 Medical Policy Genetic Testing for Colorectal Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date: Effective Date: October

More information

MRC-Holland MLPA. Description version 15;

MRC-Holland MLPA. Description version 15; probemix P036-E1 HUMAN TELOMERE-3 Lot E1-0910, E1-1208, E1-0808. As compared to version D2 (lot D2-0408), the probes for 1p and 4q have been replaced. Approximately 3-8% of all cases of mental retardation

More information

Product Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Product Description SALSA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. As compared to version C2, 12 extra BRCA1 probes and 3 probes for exon 24 have been included, and

More information

TumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer

TumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer TumorNet-Lynch genetic testing for hereditary colorectal or uterine cancer What Are the Causes of Hereditary Colorectal Cancer? sporadic 70% familial 20% hereditary 10% Lynch syndrome, up to 4% Familial

More information

Development of Carcinoma Pathways

Development of Carcinoma Pathways The Construction of Genetic Pathway to Colorectal Cancer Moriah Wright, MD Clinical Fellow in Colorectal Surgery Creighton University School of Medicine Management of Colon and Diseases February 23, 2019

More information

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696 Index Note: Page numbers of article titles are in boldface type. A Adenomatous polyposis, familial. See Familial adenomatous polyposis. Anal anastomosis, ileal-pouch, proctocolectomy with, in FAP, 591

More information

Lynch Syndrome. Angie Strang, PGY2

Lynch Syndrome. Angie Strang, PGY2 Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system

More information

Anatomic Molecular Pathology: An Emerging Field

Anatomic Molecular Pathology: An Emerging Field Anatomic Molecular Pathology: An Emerging Field Antonia R. Sepulveda M.D., Ph.D. University of Pennsylvania asepu@mail.med.upenn.edu 2008 ASIP Annual Meeting Anatomic pathology (U.S.) is a medical specialty

More information

LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)!

LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! LYNCH SYNDROME: IN YOUR FACE BUT LOST IN SPACE (MOUNTAIN)! Kathryn Singh, MPH, MS, LCGC Associate Clinical Professor Assistant Director, Graduate Program in Genetic Counseling Division of Genetic and Genomic

More information

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our

Supplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our 1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented

More information

Case Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014

Case Study. Overview. Deleterious MLH1 mutation detected on sequencing 10/16/2014 The Role of Next Generation Sequencing for Hereditary Cancer Syndromes: A Focus on Endometrial Cancer Laura J. Tafe, MD Assistant Professor of Pathology Assistant Director, Molecular Pathology Dartmouth-Hitchcock

More information

Product Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Product Description SALSA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. For a complete product history see page 11. Catalogue numbers: P002-025R: SALSA MLPA probemix P002

More information

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA

OverView Circulating Nucleic Acids (CFNA) in Cancer Patients. Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA OverView Circulating Nucleic Acids (CFNA) in Cancer Patients Dave S.B. Hoon John Wayne Cancer Institute Santa Monica, CA, USA cfna Blood Assays Cell-free nucleic acids as biomarkers in cancer patients.

More information

Serrated Polyps and a Classification of Colorectal Cancer

Serrated Polyps and a Classification of Colorectal Cancer Serrated Polyps and a Classification of Colorectal Cancer Ian Chandler June 2011 Structure Serrated polyps and cancer Molecular biology The Jass classification The familiar but oversimplified Vogelsteingram

More information

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By HENRY T. LYNCH, M.D. 1 Could this be hereditary Colon Cancer 4 Creighton University School of Medicine Omaha, Nebraska Magnitude of the Problem Annual

More information

SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced.

SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced. SALSA MLPA KIT P036-E1 HUMAN TELOMERE-3 Lot 0808: As compared to the previous version (P036-D2), the probes for 1p and 4q have been replaced. MENTAL RETARDATION is caused by aberrant copy numbers of subtelomeric

More information

Product Description SALSA MLPA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol.

Product Description SALSA MLPA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol. Product Description SALSA Probemix P015-F2 MECP2 To be used with the MLPA General Protocol. Version F2. Compared to version F1, two reference probes have been replaced and the 118 nt Y fragment has been

More information

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014

COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 COLON CANCER & GENETICS VERMONT COLORECTAL CANCER SUMMIT NOVEMBER 15, 2014 WENDY MCKINNON, MS, CGC CERTIFIED GENETIC COUNSELOR FAMILIAL CANCER PROGRAM UNIVERSIT Y OF VERMONT MEDICAL CENTER 1 CHARACTERISTICS

More information

A Review from the Genetic Counselor s Perspective

A Review from the Genetic Counselor s Perspective : A Review from the Genetic Counselor s Perspective Erin Sutcliffe, MS, CGC Certified Genetic Counselor Cancer Risk Evaluation Program INTRODUCTION Errors in base pair matching that occur during DNA replication,

More information

The Next Generation of Hereditary Cancer Testing

The Next Generation of Hereditary Cancer Testing The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,

More information

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: 2.04.08 Last Review: 1/2018 Origination: 1/2004 Next Review: 1/2019 Policy Blue Cross and Blue Shield of Kansas

More information

Information for You and Your Family

Information for You and Your Family Information for You and Your Family What is Prevention? Cancer prevention is action taken to lower the chance of getting cancer. In 2017, more than 1.6 million people will be diagnosed with cancer in the

More information

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Putting NICE guidance into practice Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27) Published: February 2017 Summary Molecular testing strategies

More information

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP

Colon cancer: practical molecular diagnostics. Wade S. Samowitz, M.D. University of Utah and ARUP Colon cancer: practical molecular diagnostics Wade S. Samowitz, M.D. University of Utah and ARUP Disclosure Dr. Samowitz may receive royalties in the future related to the Ventana BRAF V600E antibody.

More information

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer Start date: May 2015 Review date: April 2018 1 Background Mismatch repair (MMR) deficiency is seen in approximately 15%

More information

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research

Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,

More information

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer March 2017 1 Background Mismatch repair (MMR) deficiency is seen in approximately

More information

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Policy Number: Original Effective Date: MM.02.007 09/01/2011 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration

More information

MSI positive MSI negative

MSI positive MSI negative Pritchard et al. 2014 Supplementary Figure 1 MSI positive MSI negative Hypermutated Median: 673 Average: 659.2 Non-Hypermutated Median: 37.5 Average: 43.6 Supplementary Figure 1: Somatic Mutation Burden

More information

The molecular genetics of colorectal cancer

The molecular genetics of colorectal cancer 1 Department of Gastroenterology, North Middlesex University Hospital, London, UK 2 Institute of Molecular Genetics, Cardiff University 3 Department of Gastroenterology, Queen s Hospital Romford, London,

More information

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease) CANCER Affects 25% of US population Kills 19% of US population (2nd largest killer after heart disease) NOT one disease but 200-300 different defects Etiologic Factors In Cancer: Relative contributions

More information

DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document

DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document Molecular testing strategies for Lynch syndrome in The National Institute for Health

More information

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes

Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Genetic Testing for Lynch Syndrome and Other Inherited Colon Cancer Syndromes Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,

More information

Lynch Syndrome and COLARIS Testing

Lynch Syndrome and COLARIS Testing Lynch Syndrome and COLARIS Testing Webinar Objectives Review of Lynch syndrome as a multi-gene disorder COLARIS Enhancements Technical Overview COLARIS test offerings Test development and validation process

More information

Management of higher risk of colorectal cancer. Huw Thomas

Management of higher risk of colorectal cancer. Huw Thomas Management of higher risk of colorectal cancer Huw Thomas Colorectal Cancer 41,000 new cases pa in UK 16,000 deaths pa 60% 5 year survival Adenoma-carcinoma sequence (Morson) Survival vs stage (Dukes)

More information

Colon Cancer and Hereditary Cancer Syndromes

Colon Cancer and Hereditary Cancer Syndromes Colon Cancer and Hereditary Cancer Syndromes Gisela Keller Institute of Pathology Technische Universität München gisela.keller@lrz.tum.de Colon Cancer and Hereditary Cancer Syndromes epidemiology models

More information

Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes

Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes Genetic Testing for Lynch Syndrome and Inherited Intestinal Polyposis Syndromes Policy Number: 2.04.08 Last Review: 1/2014 Origination: 1/2004 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas

More information

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto Immunohistochemical Assessment of Mismatch Repair Proteins in Endometrial Cancer: The Whys and How Terence J. Colgan, MD Head of Gynaecological Pathology, Mount Sinai Hospital, University of Toronto, Toronto.

More information

Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation

Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Collaboration between CEQAS and UK NEQAS for Molecular Genetics Solid Tumour EQAs and variant interpretation Dr Jenni Fairley Deputy Scheme Director (Molecular Pathology), GenQA, Edinburgh, UK From 1 st

More information

American Society of Cytopathology Core Curriculum in Molecular Biology

American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology American Society of Cytopathology Core Curriculum in Molecular Biology Chapter 1 Molecular Basis of Cancer Molecular Oncology Keisha

More information

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome

Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines

More information

New Strategy For Treatment Of Hereditary Colorectal Cancer By Shozo Baba

New Strategy For Treatment Of Hereditary Colorectal Cancer By Shozo Baba New Strategy For Treatment Of Hereditary Colorectal Cancer By Shozo Baba If you are looking for a book by Shozo Baba New Strategy for Treatment of Hereditary Colorectal Cancer in pdf form, then you have

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Genetic Testing for Lynch Syndrome and Other Inherited Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Genetic Testing for Lynch Syndrome and Other

More information

ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES

ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY OBJECTIVES ASSESSMENT OF MLH1 PROMOTER METHYLATION IN ENDOMETRIAL CANCER USING PYROSEQUENCING TECHNOLOGY Authors: Duilio Della Libera, Alessandra D Urso, Federica Modesti, Georgeta Florea, Marta Gobbato Hospital:

More information

Introduction. Why Do MSI/MMR Analysis?

Introduction. Why Do MSI/MMR Analysis? Clinical Significance Of MSI, KRAS, & EGFR Pathway In Colorectal Carcinoma UCSF & Stanford Current Issues In Anatomic Pathology Introduction Microsatellite instability and mismatch repair protein deficiency

More information

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer COLORECTAL PATHWAY GROUP, MANCHESTER CANCER Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer January 2015 1 Background Mismatch repair (MMR) deficiency is seen in approximately

More information

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr

Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Pr Case Presentation Diana Lim, MBBS, FRCPA, FRCPath Senior Consultant Department of Pathology, National University Health System, Singapore Assistant Professor Yong Loo Lin School of Medicine, National University

More information

Supplementary Figure 1. Estimation of tumour content

Supplementary Figure 1. Estimation of tumour content Supplementary Figure 1. Estimation of tumour content a, Approach used to estimate the tumour content in S13T1/T2, S6T1/T2, S3T1/T2 and S12T1/T2. Tissue and tumour areas were evaluated by two independent

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_colon_cancer 5/2004 8/2017 8/2018 8/2017 Description of Procedure or Service Genetic

More information

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian

Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell

More information

Universal Screening for Lynch Syndrome

Universal Screening for Lynch Syndrome Universal Screening for Lynch Syndrome St. Vincent/Ameripath protocol proposal Lynch syndrome (HNPCC) 1/35 individuals with colorectal cancer has Lynch syndrome Over half individuals are >50 at time of

More information

Germline Testing for Hereditary Cancer with Multigene Panel

Germline Testing for Hereditary Cancer with Multigene Panel Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with

More information